

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENT**


Docket Number (Optional)
20695C-003420US

In re Application of: Heinz Redl, et al.

Application No.: 10/749,832

Filed: 12/30/03

For: FIBRIN/FIBRINOGEN-BINDING CONJUGATE



The owner*, BAXTER AKTIENGESellschaft, of 50 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term **prior patent No.**

6,506,365 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said **prior patent** is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:


- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.


Check either box 1 or 2 below, if appropriate.

1. ☒ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☐ The undersigned is an attorney or agent of record. Reg. No. _____


Signature
Michael C. Schiffer
Typed or printed name


Date

(949) 474-6405
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

60520050 v1

01/20/2006 HTECKLU1 00000006 201430 10749832

01 FC:1814 130.00 DA

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Heinz Redl, et al.Application No./Patent No.: 10/749,832 Filed/Issue Date: 12/30/03Entitled: FIBRIN/FIBRINOGEN-BINDING CONJUGATEBAXTER AKTIENGESSELLSCHAFT, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☒ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is 50 %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012367, Frame 0489, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To : _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To : _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To : _____


The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


Signature

Michael C. Schiffer

Printed or Typed Name

Jan 13, 2008
Date

(949) 474-6405

Telephone Number

Additional Authorized Representative

Title



Baxter

AUTHORIZATION

We, BAXTER Aktiengesellschaft, Industriestrasse 67, 1220 Vienna, Austria, hereby authorize

Mr. Michael C. Schiffer, Esq.
Baxter Healthcare Corporation
17511 Armstrong Avenue
Irvine, California 92614
USA

to represent our company in all patent- and trademark related matters, in particular to exercise all instruments necessary to perfect or transfer intellectual property rights, to exercise and sign on our behalf patent applications, trademark applications, affidavits, license agreements, patent and/or trademark cancellations, oppositions and any other ancillary documents in connection with patents and/or trademarks.

This Authorization is valid until further notice.

Vienna, July 24, 2000

BAXTER Aktiengesellschaft

Gordon Busenbark
VP General Manager